Charlotte's Web Holdings, Inc. 2018 Farm Bill

Charlotte's Web Holdings, Inc.

Consumer Products

BUY Company Update unchanged PRICE TARGET C$21.00 unchanged 2018 Farm Bill delayed as anticipated Price (28-Sep) C$15.01 Ticker CWEB-CNSX Investment recommendation: We are reiterating our BUY rating and target price of C$21.00 amidst an anticipated 52-Week Range (C$): 9.05 - 18.00 delay in the passing of the 2018 Farm Bill. Market Cap (C$M): 1,579 Investment highlights: Shares Out. (M) : 105.2 Implied Return to Target (%) : 39.9 • With the existing Farm Bill having expired on September 30, the passing of the 2018 Net Debt (Cash) (C$M): (94) Farm Bill is now officially delayed. While this was widely anticipated, and we do not Enterprise Value (C$M): 1,485 believe this will have any material impact on the operations of Charlotte’s Web, the FYE Dec 2017A 2018E 2019E 2020E delay will extend Industrial Hemp’s status as a Schedule I Controlled Substance until Sales (US$M) 40.0 79.9 169.5 296.6 the bill is signed into law. As a reminder, the 2018 Farm Bill has passed the House of Representatives as well as the Senate and is now with a conference committee to Gross Profit 29.9 61.7 125.8 219.5 (US$M) reconcile the differences between the bill’s two versions. Importantly, the Senate’s EBITDA (US$M) 14.1 28.3 59.0 98.9 version of the bill contains key regulation relating to industrial hemp, the Hemp EPS (US$) 0.09 0.20 0.37 0.65 Farming Act of 2018, and passed the Senate with a vote of 86-11. EV/EBITDA (x) 80.6 40.3 19.3 11.5 P/E (x) 131.1 57.4 31.0 17.8 • While the regulation relating to hemp was only included in the Senate version of the Farm Bill, we do not anticipate this to be a contentious issue as the Hemp Farming 19 18 Act has strong bipartisan support, with Senate Republican leader Mitch McConnell 17 sponsoring the Hemp Farming Act and Senate Democratic leader Chuck Schumer 16 acting as a co-sponsor. As well, we note that Senator McConnell as well as two other 15 co-sponsors sit on the Farm Bill conference committee. While there have been various 14 reasons for the delay of the Farm Bill, the contentious issues are of no relation to the 13 proposed hemp regulation and have focused mainly on the Supplemental Nutrition 12 Assistance Program, unrelated to the operations of Charlotte’s Web. 11 • The Hemp Farming Act is set to remove hemp (and all derivatives/extracts) from the 10 definition of marijuana, de-scheduling hemp and removing it from the scope of the 9 DEA. If passed, Industrial Hemp would become classified as an agricultural commodity, allowing for the distribution between states and falling within the scope of the USDA. Sep-18 CWEB • In our view, the de-scheduling of hemp is transformational for the hemp extracts Source: FactSet industry, as we believe it will support further acceptance at both a consumer and retailer level. We anticipate national grocery and drug store chains will look to partner Priced as of close of business 28 September 2018 with hemp-derived extract manufacturers and, in our view, Charlotte’s Web is very well Charlotte’s Web is a market leader in the production positioned to be the first hemp-derived CBD company to sell through mass market and distribution of wellness products made from retailers. While we have not included large national grocery distribution agreements cannabidiol, a compound extracted from industrial into our estimates, we believe this would add meaningful upside to our valuation. hemp. Based in Boulder, Colorado, Charlotte's Web markets its products to customers across the United Valuation: States and on a limited basis internationally, through Our target price is derived using a DCF valuation, with an 11.1% WACC and 2.5% terminal specialty retailers and its website (www.cwhemp.com). growth rate, yielding a value per share of C$21.00. Our target implies 16.4x our 2020 All figures expressed in US$ unless otherwise stated EBITDA estimate of $99 million, which we convert to Canadian dollars to account for the company’s CSE-listed share price. Charlotte’s Web offers investors exposure to the high- growth CBD supplements market, through its industry-leading market share, impressive management team, established and growing retail relationships, and strong brand power. With the shares currently trading at 11.5x our 2020 EBITDA estimate, we believe Charlotte’s Web represents an attractive buying opportunity.

Canaccord Genuity is the global capital markets group of Canaccord Genuity Group Inc. (CF : TSX) The recommendations and opinions expressed in this research report accurately reflect the research analyst's personal, independent and objective views about any and all the companies and securities that are the subject of this report discussed herein. For important information, please see the Important Disclosures beginning on page 5 of this document. Charlotte's Web Holdings, Inc. Company Update

2018 Farm Bill delayed as expected With the existing Farm Bill having expired on September 30, the last day of the United States Federal Government’s fiscal year, the passing of the 2018 Farm Bill is now officially delayed. While this was widely anticipated, and we do not believe this will have any material impact on the operations of Charlotte’s Web, the delay will extend Industrial Hemp’s status as a Schedule I Controlled Substance until the bill is signed into law. Bipartisan support for pro-hemp regulations remains intact As a reminder, the 2018 Farm Bill has passed the House of Representatives as well as the Senate and is now with a conference committee to reconcile the differences between the bill’s two versions. Importantly, the Senate’s version of the bill contains key regulation relating to industrial hemp, the Hemp Farming Act of 2018, and passed the Senate with a vote of 86-11. While the regulation relating to hemp was only included in the Senate version of the Farm Bill, we do not anticipate this to be a contentious issue as the Hemp Farming Act has strong bipartisan support, with Senate Republican leader Mitch McConnell sponsoring the Hemp Farming Act and Senate Democratic leader Chuck Schumer acting as a co-sponsor. As well, we note that Senator McConnell as well as two other co-sponsors sit on the Farm Bill conference committee. While there have been various reasons for the delay of the Farm Bill, the contentious issues are of no relation to the proposed hemp regulation and have focused mainly on the Supplemental Nutrition Assistance Program, unrelated to the operations of Charlotte’s Web. Key regulation expected to support broader acceptance of hemp extracts The Hemp Farming Act is set to remove hemp (and all derivatives/extracts) from the definition of marijuana, effectively de-scheduling hemp and removing it from the purview of the Controlled Substances Act and the scope of the DEA. If passed, industrial hemp would become classified as an agricultural commodity, allowing for the distribution between states and falling within the scope of the USDA. In our view, the de-scheduling of hemp is transformational for the hemp-derived extracts industry, as we believe it will support further acceptance at both a consumer and retailer level. We anticipate national grocery and drug store chains will look to partner with hemp-derived extract manufacturers, increasing the presence of these products on shelf. In our view, Charlotte’s Web is very well positioned to be the first hemp-derived CBD company to sell through mass market retailers. While we have not included large national grocery distribution agreements into our estimates, we believe this would add meaningful upside to our valuation. Figure 1: Sensitivity analysis of incremental EBITDA for mass market distribution ($000s) # Stores 5,470 500 750 1,000 1,250 1,500 28.2% 2,395 3,593 4,790 5,988 7,185 30.2% 2,565 3,847 5,130 6,412 7,695 EBITDA % 32.2% 2,735 4,102 5,470 6,837 8,204 34.2% 2,905 4,357 5,809 7,262 8,714 36.2% 3,074 4,612 6,149 7,686 9,223 Source: Company Reports, Canaccord Genuity estimates

2 Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 2

Charlotte's Web Holdings, Inc. Company Update

Valuation Our target price is derived using a DCF valuation, with an 11.1% WACC and 2.5% terminal growth rate, yielding a value per share of $21.00. Our target implies 16.4x our 2020 EBITDA estimate of $99 million, which we convert to Canadian dollars to account for the company’s CSE-listed share price. Charlotte’s Web offers investors exposure to the high-growth CBD supplements market, through its industry-leading market share, impressive management team, established and growing retail relationships, and strong brand power. With the shares currently trading at 11.5x our 2020 EBITDA estimate, we believe Charlotte’s Web represents an attractive buying opportunity. Figure 2: Historical NTM EV/EBITDA multiple

18.0x 17.0x 16.0x 15.0x 14.0x 13.0x 12.0x 11.0x 10.0x 9.0x Sep-15 Mar-16 Sep-16 Mar-17 Sep-17 Mar-18 Sep-18 Health and wellness supplement manufacturers

Source: Company Reports, Canaccord Genuity estimates

3 Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 3

Charlotte's Web Holdings, Inc. Company Update

Figure 3: Comparable valuations

Share and Earnings Information By Company Shrs Mark et Enterprise Value / O/S Cap. Enterpri se EBITDA/Revenue YoY EBITDA Growth EBITDA Ratios Company Name TK Pri ce (ml n) (ml n) Value (mln) LFY FY1 FY2 FY3 FY1/LFY FY2/FY1 FY3/FY2 LFY FY1 FY2 FY3 Supplement manufacturers Glanbia Plc GL9-IE $14.69 295.8 $4,345 $4,747 13.8% 13.8% 14.1% 14.3% -1.4% 7.0% 7.2% 14.4 14.6 13.6 12.7 USANA Health Sciences, Inc. USNA-US $120.55 24.8 $2,995 $2,696 15.4% 18.0% 18.1% n.a. 33.2% 8.7% n.a 16.7 12.6 11.5 n.a. Blackmores Limited BKL-AU $132.38 17.2 $2,283 $2,332 18.5% 17.8% 18.9% 19.9% 20.6% 17.8% 17.5% 20.9 17.4 14.7 12.5 Jamieson Wellness, Inc. JWEL-CA $26.66 39.8 $1,061 $1,226 20.5% 20.4% 21.8% 22.4% 10.9% 14.9% 9.9% 19.9 18.0 15.6 14.2 Group Average 17.1% 17.5% 18.2% 18.9% 15.8% 12.1% 11.5% 18.0 15.6 13.9 13.2 CBD product manufacturers CV Sciences, Inc. CVSI-US $4.83 112.5 $543 $537 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Isodiol International Inc ISOL-CA $3.70 30.1 $111 $96 n.a. n.a. 19.3% 21.3% n.a. n.a. 32.9% n.a. n.a. 7.5 5.6 Elixinol Global Ltd. EXL-AU $2.00 102.9 $206 $187 n.a. 5.4% 13.5% 14.3% n.a. n.a. 47.5% n.a. 104.1 30.7 20.8 Xanthic Biopharma, Inc. XTHC-CA $0.25 56.8 $14 $13 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Medical Marijuana, Inc. MJNA-US $0.09 3,444 $310 $316 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. GW Pharmaceuticals PLC GWPH-US $172.74 28.2 $4,874 $4,798 n.a. n.a. n.a. 14.9% n.a. n.a. n.a. n.a. n.a. n.a. 61.7 Group Average n.a. 5.4% 16.4% 16.8% n.a. n.a. 40.2% n.a. 104.1 19.1 29.4 Cannabis oil manufacturers CannTrust Holdings, Inc. TRST-CA $12.71 108.0 $1,373 $1,285 0.2% 3.5% 14.4% 21.9% n.a. n.a. 88.4% n.a. 475.0 34.9 18.5 Tilray, Inc. TLRY-US $143.62 93.1 $13,377 $13,407 n.a. n.a. 17.0% 25.8% n.a. n.a. 230.0% n.a. n.a. 506.9 153.6 Aphria Inc APH-CA $18.00 253.8 $4,568 $4,219 29.8% 15.1% 34.4% 39.2% n.a. n.a. 154.9% 693.4 755.4 49.1 19.3 Cronos Group Inc CRON-CA $14.35 206.4 $2,962 $2,860 n.a. 24.0% 31.0% 39.5% n.a. n.a. 96.7% n.a. 339.4 62.1 31.6 Group Average 15.0% 14.2% 24.2% 31.6% n.a. n.a. 142.5% 693.4 523.3 163.2 55.7 Blended peer average 16.4% 14.8% 20.3% 23.4% 15.8% 12.1% 76.1% 153.1 217.0 74.7 35.1 Charlotte's Web Holdings, Inc.CWEB-CA $15.01 105.2 $1,579 $1,485 35.3% 35.4% 34.8% 33.3% 100.2% 108.4% 67.7% 80.6 40.3 19.3 11.5 Source: Company Reports, Canaccord Genuity estimates

4 Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 4

Charlotte's Web Holdings, Inc. Company Update

Appendix: Important Disclosures

Analyst Certification Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. Sector Coverage Individuals identified as “Sector Coverage” cover a subject company’s industry in the identified jurisdiction, but are not authoring analysts of the report.

Investment Recommendation Date and time of first dissemination: October 01, 2018, 07:35 ET Date and time of production: October 01, 2018, 07:35 ET Target Price / Valuation Methodology: Charlotte's Web Holdings, Inc. - CWEB Our target price is derived using a DCF valuation, with an 11.1% WACC and 2.5% terminal growth rate. Our C$21.00 target represents 16.4x our 2020 EBITDA estimate of $99 million, which is converted into Canadian dollars to account for the company's CSE-listed share price. Risks to achieving Target Price / Valuation: Charlotte's Web Holdings, Inc. - CWEB CBD research discovers negative side effects or lack of efficacy Despite the various reports and studies that have been conducted to evaluate the efficacy of CBD, there remains limited conclusive evidence to support the many claimed benefits of the cannabinoid. While the FDA’s recent approval of Epidiolex is a testament to the proven efficacy of CBD, the scientifically proven applications remain limited and there are multiple use cases which have yet to be empirically evaluated. As such, while further evidence supporting the use of CBD could be very positive for the company, the lack of evidence, or the emergence of evidence that showed any negative side effects of CBD, has the potential to substantially impact the demand for the products of Charlotte’s Web. FDA increases intervention in the operations of the company Currently, CBD is not generally recognized as safe by the FDA, and the Administration believes that CBD cannot be marketed as a dietary supplement as it was the subject of investigation as a new drug prior to it being marketed as a dietary supplement. Charlotte’s Web does not agree with the view of the FDA and believes that CBD was marketed in a dietary supplement or food prior to the investigations being made public. With that being said, increased involvement by the FDA would substantially impact the company’s ability to market products containing CBD. 2018 Farm Bill not signed into law The 2018 Farm Bill has passed both the House of Representatives and the Senate, and a conference committee is now reconciling the amendments made to the bill in the House and Senate before bringing it to President Trump to be signed into law. The bill contains key legislation related to the cultivation of hemp; most importantly it would de-schedule hemp as a Schedule I drug under the Controlled Substances Act. While the sentiment towards hemp is certainly improving and the Farm Bill, including the legalization of industrial hemp, is very likely to become law, failure of the pro-hemp version of the bill to become law would further complicate the legal landscape that Charlotte’s Web operates in, as cultivation of hemp is currently regulated at the state level. As such, lack of federal regulation and varying state laws may continue to create a complex legal environment for Charlotte’s Web to operate in, potentially impacting the company’s ability to secure distribution, reducing end demand. Agricultural operations risk While Charlotte’s Web is beginning to diversify its agricultural assets, now producing in Colorado, Kentucky and Oregon, there are various risks related to the growing of hemp that could hinder the company’s ability to produce high quality product. This risk is further magnified by the fact that the company’s hemp is proprietary, and Charlotte’s Web cannot easily source replacement hemp to manufacture its products. The company relies on the outdoor grow of industrial hemp and so abnormal weather patterns have the potential to negatively impact crop yields or even destroy plants. Additionally, agricultural products are vulnerable to various diseases which can reduce crop quality or even result in the death of the plant. There is no guarantee that crop yield will remain consistent, and if the quality or quantity of production is negatively impacted it may hinder the company’s ability to fulfill its demand.

Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 5 Charlotte's Web Holdings, Inc. Company Update

Increased industry competition Improving regulation that supports the production and distribution of hemp and CBD products is attracting competitors to the industry. While the industry continues to evolve, there may be competitors with greater financial or marketing resources that look to enter the space. An increased level of competition may erode the company’s competitive advantage if Charlotte’s Web is not able to adapt to the changing competitive landscape accordingly. While Charlotte’s Web maintains a market leadership position, increased distribution by a competitor at a mass market retailer could negatively impact the demand for the company’s products, particularly if it was a quality competitive offering priced below Charlotte’s Web. Relationship with Stanley Brothers The branding of Charlotte’s Web is closely affiliated with the branding and reputation of the Stanley Brothers. We believe there is a risk to the company’s branding should the Stanley Brothers distance themselves from Charlotte’s Web. Additionally, we believe there is risk associated with increased competition from the Stanley Brothers, as they currently sell cannabis extracts and oils under the Stanley Brothers brand, with limited distribution in Colorado. While we do not expect the Stanley Brothers to materially compete with Charlotte’s Web, the distancing of the Stanley Brothers name could lead to confusion in the marketplace which could negatively impact the branding of Charlotte’s Web.

Distribution of Ratings: Global Stock Ratings (as of 10/01/18) Rating Coverage Universe IB Clients # % % Buy 553 62.77% 46.11% Hold 214 24.29% 28.97% Sell 10 1.14% 30.00% Speculative Buy 104 11.80% 66.35% 881* 100.0% *Total includes stocks that are Under Review

Canaccord Genuity Ratings System BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months. HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months. SELL: The stock is expected to generate negative risk-adjusted returns during the next 12 months. NOT RATED: Canaccord Genuity does not provide research coverage of the relevant issuer. “Risk-adjusted return” refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer. Risk Qualiﬁer SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss. 12-Month Recommendation History (as of date same as the Global Stock Ratings table) A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures- mar.canaccordgenuity.com/EN/Pages/default.aspx

Required Company-Specific Disclosures (as of date of this publication) Charlotte's Web Holdings, Inc. currently is, or in the past 12 months was, a client of Canaccord Genuity or its affiliated companies. During this period, Canaccord Genuity or its affiliated companies provided investment banking services to Charlotte's Web Holdings, Inc.. In the past 12 months, Canaccord Genuity or its affiliated companies have received compensation for Investment Banking services from Charlotte's Web Holdings, Inc. . In the past 12 months, Canaccord Genuity or any of its affiliated companies have been lead manager, co-lead manager or co-manager of a public offering of securities of Charlotte's Web Holdings, Inc. or any publicly disclosed offer of securities of Charlotte's Web Holdings, Inc. or in any related derivatives. Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from Charlotte's Web Holdings, Inc. in the next three months. As of the month end immediately preceding the date of publication of this research, or the prior month end if publication is within 10 days following a month end, Canaccord Genuity or its affiliated companies, in the aggregate, beneficially owned 1% or more of any class

Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 6 Charlotte's Web Holdings, Inc. Company Update of the total issued share capital or other common equity securities of Charlotte's Web Holdings, Inc. or held any other financial interests in Charlotte's Web Holdings, Inc. which are significant in relation to the research (as disclosed below). An analyst has visited the material operations of Charlotte's Web Holdings, Inc.. No payment was received for the related travel costs.

Charlotte's Web Holdings, Inc. Rating History as of 09/28/2018 I:B:C$21.00 09/19/2018 C$22 C$20 C$18 C$16 C$14 C$12 C$10 C$8 Oct 13 Jan 14 Apr 14 Jul 14 Oct 14 Jan 15 Apr 15 Jul 15 Oct 15 Jan 16 Apr 16 Jul 16 Oct 16 Jan 17 Apr 17 Jul 17 Oct 17 Jan 18 Apr 18 Jul 18

Closing Price Price Target

Buy (B); Speculative Buy (SB); Sell (S); Hold (H); Suspended (SU); Under Review (UR); Restricted (RE); Not Rated (NR)

Past performance In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance. Online Disclosures Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to [email protected]. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above. General Disclaimers See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 50%-owned by Canaccord Genuity Group Inc. The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne. The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity’s policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity’s policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity’s judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 7 Charlotte's Web Holdings, Inc. Company Update

From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research. This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research. Research Distribution Policy Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm's research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent. For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative. Short-Term Trade Ideas Research Analysts may, from time to time, discuss “short-term trade ideas” in research reports. A short-term trade idea offers a near- term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long- term ‘Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or “Speculative Buy’ could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity’s research. For Canadian Residents: This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory. For United States Persons: Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. For United Kingdom and European Residents: This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005

Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 8 Charlotte's Web Holdings, Inc. Company Update

(as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority. For Jersey, Guernsey and Isle of Man Residents: This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser. CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc. For Australian Residents: This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited. Canaccord Genuity Wealth Management is a division of Canaccord Genuity (Australia) Limited. For Hong Kong Residents: This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research. Additional information is available on request. Copyright © Canaccord Genuity Corp. 2018 – Member IIROC/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited. 2018 – Member LSE, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2018 – Member FINRA/SIPC Copyright © Canaccord Genuity (Australia) Limited. 2018 – Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and regulated by ASIC. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above. None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

Buy unchanged Target Price C$21.00 unchanged | 1 October 2018 Consumer Products 9